` ATRA (Atara Biotherapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ATRA
vs
S&P 500

Over the past 12 months, ATRA has underperformed S&P 500, delivering a return of -3% compared to the S&P 500's 9% growth.

Stocks Performance
ATRA vs S&P 500

Loading
ATRA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ATRA vs S&P 500

Loading
ATRA
S&P 500
Difference
www.alphaspread.com

Performance By Year
ATRA vs S&P 500

Loading
ATRA
S&P 500
Add Stock

Competitors Performance
Atara Biotherapeutics Inc vs Peers

S&P 500
ATRA
ABBV
AMGN
GILD
VRTX
Add Stock

Atara Biotherapeutics Inc
Glance View

Market Cap
53.7m USD
Industry
Biotechnology

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.

ATRA Intrinsic Value
19.66 USD
Undervaluation 59%
Intrinsic Value
Price
Back to Top